Tetraphase Pharmaceuticals, Inc. engages in the development and production of novel tetracyclines for serious and life-threatening bacterial infections. The company is headquartered in Watertown, Massachusetts and currently employs 119 full-time employees. The firm uses its chemistry technology to create antibiotics for multidrug-resistant infections. The firm is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections. The firm also develops TP-6076 for multidrug-resistant gram-negative infections. Eravacycline is a fluorocycline antibiotic. The firm is conducting a global Phase III clinical program for eravacycline called Investigating Gram-Negative Infections Treated with Eravacycline (IGNITE). TP-271 is a fully synthetic fluorocycline being developed for respiratory disease caused by bacterial biothreat pathogens in healthy volunteers.